Exhibit
10.1


 


[FORM
OF] SECURITIES PURCHASE AGREEMENT


 


This
Securities Purchase Agreement (this “Agreement”) is dated as of October 15, 2020, by and among Nephros, Inc.,
a Delaware corporation (the “Company”), and the purchasers identified on the signature page hereto (including
each purchaser’s successors and assigns, individually, a “Purchaser,” and collectively, the “Purchasers”).



 


WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the
Securities Act of 1933, as amended (the “Securities Act”), the Company desires to issue and sell to the Purchasers,
and the Purchasers desire to purchase from the Company, securities of the Company as more fully described in this Agreement. 


 


NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers agree as follows: 


 


ARTICLE
I.

DEFINITIONS


 


1.1
Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings set forth
in this Section 1.1: 


 


“Closing”
means the closing of the purchase and sale of the Shares pursuant to Section 2.1. 


 


“Closing
Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (a) the Purchasers’ obligations to pay the Subscription Amount and (b)
the Company’s obligations to deliver the Shares, in each case, have been satisfied or waived, but in no event later than
the third Trading Day following the date hereof. 


 


“Commission”
means the United States Securities and Exchange Commission. 


 


“Common
Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed. 


 


“Fundamental
Transaction” means any of the following:
(a) the Company effects any merger or consolidation of the Company with or into another Person, (b) the Company effects any sale
of all or substantially all of its assets in one or a series of related transactions, (c) any tender offer or exchange offer (whether
by the Company or another person) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their
shares for other securities, cash or property, or (d) the Company effects any reclassification of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property.


 


“Material
Adverse Effect” means (a) a material
adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company
and its subsidiaries, taken as a whole, or (b) a material adverse effect on the Company’s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document. 


 




    	 



    	 



    

 


“Offering”
means the sale of the Shares to the Purchasers.


 


“Per
Share Purchase Price” equals $6.00, subject to adjustment for reverse and forward stock splits, stock dividends, stock
combinations and other similar transactions of the Common Stock that occur after the date of this Agreement but on or prior to
the Closing Date. 


 


“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 


 


“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened. 


 


“Prospectus”
means the final prospectus included in the Registration Statement. 


 


“Prospectus
Supplement” means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with
the Commission and delivered by the Company to the Purchasers. 


 


“Registration
Statement” means the effective registration statement on Form S-3 filed with the Commission (File No. 333-234528) that
registers the offer and sale of the Shares. 


 


“Shares”
means the shares of Common Stock issued or issuable to the Purchasers pursuant to this Agreement. 


 


“Subscription
Amount” means the aggregate amount to be paid for the Shares purchased hereunder as specified below each Purchaser’s
name on the signature page of this Agreement and next to the heading “Subscription Amount” in United States dollars
and in immediately available funds. 


 


“Trading
Day” means a day on which the principal Trading Market is open for trading. 


 


“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
the New York Stock Exchange or the OTCQB Venture Market (or any successors to any of the foregoing). 


 


“Transaction
Documents” means this Agreement and any other documents or agreements executed in connection with the transactions contemplated
hereunder. 


 


“Transfer
Agent” means VStock Transfer, LLC, 18 Lafayette Place, Woodmeer, NY 11598, and any successor transfer agent of the Company.



 




    	2



    	 



    

 


ARTICLE
II.

PURCHASE AND SALE 


 


2.1
Closing. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell,
and each Purchaser agrees to purchase, the Shares identified on such Purchaser’s signature page hereto. At the Closing,
each Purchaser shall deliver to the Company, via wire transfer, immediately available funds equal to such Purchaser’s Subscription
Amount, the Company shall deliver to the Purchasers the Shares as set forth in Section 2.3(a), and the Company and each Purchaser
shall deliver the other items set forth in Section 2.3 deliverable at the Closing. Upon satisfaction of the covenants and conditions
set forth in Sections 2.3 and 2.4, the Closing shall occur at such location or by electronic exchange of documents, as the parties
shall mutually agree. 


 


2.2
Prospectus. Each Purchaser represents
and warrants to the Company that it has received (or otherwise had made available to it by the filing by the Company of an electronic
version thereof with the Commission) the Prospectus filed by the Company with the Commission and, if applicable, certain “free
writing prospectuses” (as that term is defined in Rule 405 under the Securities Act), that have been or will be filed with
the Commission and delivered to the Purchaser on or prior to the date hereof, containing certain supplemental information regarding
the Shares, the terms of the Offering and the Company, and the Prospectus Supplement. Each Purchaser acknowledges that, prior
to the delivery of this Agreement by the Purchaser to the Company, the Purchaser will receive certain additional information regarding
the Offering, including pricing information. Such information may be provided to the Purchaser by any means permitted under the
Securities Act, including the Prospectus Supplement, a free writing prospectus and oral communications.


 


2.3
Deliveries. 


 


(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchasers the following: 


 


(i)
this Agreement, duly executed by the Company; 


 


(ii)
a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver a number of Shares equal
to each Purchaser’s Subscription Amount, designated on the signature page as “Subscription Amount,” divided
by the Per Share Purchase Price for Common Stock, registered in the name of such Purchaser, via The Depository Trust Company (DTC)
Deposit and Withdrawal at Custodian (DWAC) system; 


 


(iii)
a certificate of the Secretary of the Company, dated as of the Closing Date, (A) certifying the resolutions adopted by the Board
of Directors of the Company or by any committee of the Board of Directors of the Company approving the transactions contemplated
by this Agreement and the other Transaction Documents and the issuance of the Shares and (B) certifying the current versions of
the certificate of incorporation and by-laws of the Company; 


 




    	3



    	 



    

 


(iv)
a certificate of the Chief Executive Officer of the Company, dated as of the Closing Date, certifying to the fulfillment of the
conditions specified in Sections 2.4(b)(i) and (iii); 


 


(v)
a legal opinion of Fredrikson & Byron, P.A. (“F&B”), as counsel to the Company; and 


 


(vi)
the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act). 


 


(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following: 


 


(i)
this Agreement, duly executed by such Purchaser; and 


 


(ii)
such Purchaser’s Subscription Amount by wire transfer to the account specified in writing by the Company. 


 


2.4
Closing Conditions. 


 


(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met: 


 


(i)
all obligations, covenants and agreements of the Purchasers required to be performed at or prior to the Closing Date shall have
been performed; and 


 


(ii)
the delivery by the Purchasers of the items set forth in Section 2.3(b) of this Agreement. 


 


(b)
The obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:



 


(i)
all obligations, covenants and agreements of the Company under this Agreement required to be performed at or prior to the Closing
Date shall have been performed; 


 


(ii)
the delivery by the Company of the items set forth in Section 2.3(a) of this Agreement; 


 


(iii)
there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and 


 


(iv)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company’s
principal Trading Market, and, from the date hereof and at any time prior to the Closing Date, trading in securities generally
as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities
whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either
by the United States or New York State authorities, nor shall there have occurred any material outbreak or escalation of hostilities
or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial
market which, in each case, makes it reasonably impracticable or inadvisable to purchase the Shares at the Closing.


 




    	4



    	 



    

 


ARTICLE
III.

MISCELLANEOUS 


 


3.1
Termination. This Agreement may be terminated by the Purchasers or by the Company by written notice to the other party
if the Closing has not been consummated on or before October 20, 2020; provided, however, that no such termination will affect
the right of either party to sue for any breach by the other party. 


 


3.2
Fees and Expenses. Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts,
if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance
of this Agreement. The Company shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection
with the delivery of any Shares to the Purchasers. 


 


3.3
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been
merged into such documents, exhibits and schedules. 


 


3.4
Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written
instrument signed, in the case of an amendment, by the Company and the Purchasers, or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or
requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or
a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise
any right hereunder in any manner impair the exercise of any such right. 


 


3.5
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written
consent of the Purchasers (except if in connection with a Fundamental Transaction). 


 


3.6
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns only, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. 


 




    	5



    	 



    

 


3.7
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard
to the principles of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a
party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to
the exclusive jurisdiction of the state and federal courts sitting in the City of New York for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to
the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, or that such court is an improper or inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served
in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address for notice set forth on the signature page hereto and agrees that such service shall constitute good
and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
serve process in any other manner permitted by law. If any party shall commence a Proceeding to enforce any provisions of the
Transaction Documents, then the prevailing party in such Proceeding shall be reimbursed by the other party for its reasonable
attorneys’ fees and other reasonable costs and expenses incurred with the investigation, preparation and prosecution of
such Proceeding. 


 


3.8
Execution. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including
..pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for
all purposes.


 


3.9
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable. 


 


3.10
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties
agree that monetary damages would not be adequate compensation for any loss incurred by reason of any breach of obligations contained
in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate. 


 




    	6



    	 



    

 


3.11
Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction
Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way
for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained
herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed
to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption
that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated
by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without
limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary
for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented
by its own separate legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide
all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required
or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement
and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers
collectively and not between and among the Purchasers.


 


3.12
Acknowledgment. Each Purchaser acknowledges that the Offering is not being underwritten and that there is no minimum Subscription
Amount. Such Purchaser confirms that it has had full access to all filings made by the Company with the Commission, including
the Registration Statement, the Prospectus and the Prospectus Supplement relating to the Shares, and the documents incorporated
by reference therein, and that it was able to read and review each such filing. In subscribing to the Shares, such Purchaser affirms
that it has conducted substantive due diligence with respect to the Company and the Shares including, without limitation, reviewing
in detail the Registration Statement (including the exhibits thereto), the Prospectus and the Prospectus Supplement, including
the documents incorporated by reference in such documents. In addition, such Purchaser understands that there is a high degree
of risk in subscribing to the Shares and that such Purchaser may lose the entire investment in the Shares.


 


3.13
Liquidated Damages. The Company’s obligation to pay Transfer Agent fees, stamp taxes and other taxes and duties levied
in connection with the delivery of any Shares to the Purchasers is a continuing obligation of the Company and shall not terminate
until all such unpaid amounts have been paid. 


 


3.14
Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity
to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to
be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments
thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be
subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions
of the Common Stock that occur after the date of this Agreement but on or prior to the Closing Date. 


 


3.15
Waiver of Conflict of Interest. Each Purchaser and the Company is aware that F&B may have previously performed and
may continue to perform certain legal services for certain of the Purchasers or their affiliates in matters unrelated to F&B’s
representation of the Company. In connection with its Purchaser representation, F&B may have obtained confidential information
of such Purchasers that could be material to F&B’s representation of the Company in connection with negotiation, execution
and performance of this Agreement. By signing this Agreement, each Purchaser and the Company hereby acknowledges that the terms
of this Agreement were negotiated between the Purchasers and the Company and are fair and reasonable and waives any potential
conflict of interest arising out of such representation (including any future representation of such parties) or such possession
of confidential information. Each Purchaser and the Company further represents that it has had the opportunity to be, or has been,
represented by independent counsel in giving the waivers contained in this Section 3.15. 


 


3.16
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER
PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 


 


[Signature
Pages Follow]


 




    	7



    	 



    

 


IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective
authorized signatories as of the date first indicated above. 


 


NEPHROS,
INC.


 


	By:	/s/
    Andrew Astor	 
	Name:	Andrew
    Astor	 
	Title:
    	Chief
    Executive Officer	 


 


Address
for Notice: 


 


380
Lackawanna Place


South
Orange, NJ 07079


Attn:
Chief Executive Officer


Fax:
(201) 343-5207


Email:
andy@nephros.com


 


With
a copy to (which will not constitute notice):


 


Fredrikson
& Byron, P.A.


200
South Sixth Street, Suite 4000


Minneapolis,
MN 55402


Attn:
Christopher J. Melsha, Esq.


Fax:
(612) 492-7077


Email:
cmelsha@fredlaw.com


 


Signature
Page to Securities Purchase Agreement


 




    	 



    	 



    

 


IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective
authorized signatories as of the date first indicated above. 


 


	Name
    of Purchaser:	 
		 
	Signature
    of Authorized Signatory of Purchaser:	 
	 	 
	Name
    of Authorized Signatory:	 
	 	 
	Title
    of Authorized Signatory:	 
	 	 
	Email
    Address of Authorized Signatory:	 
	 	 
	Address
    for Notice to Purchaser:	 
	 	 
	 	 
	 	 
	 	 
	 	 
	DTC
    Participant Account Name:	 
	 	 
	DTC
    Participant Account Number:	 
	 	 
	Subscription
    Amount:	$
	 	 
	Shares:	 
	 	 
	FEIN:	 


 


Signature
Page to Securities Purchase Agreement